The enVVe® System

First-In-Class, Non-Surgical Replacement Venous Valve for the Treatment of the Permanently Damaged Valves in the Deep Veins of the Leg

First-In-Class, Non-Surgical Replacement Venous Valve for the Treatment of the Permanently Damaged Valves in the Deep Veins of the Leg

enVVe® is a first-in-class replacement venous valve designed to treat severe DVI through a minimally invasive, catheter-based procedure. The procedure is performed without the need for open surgery or an overnight hospital stay.

Built on the clinical foundation of our VenoValve® surgical replacement venous valve, enVVe is our next-generation, non-surgical replacement valve. In addition to being less invasive, enVVe also incorporates design enhancements intended to improve performance, strength and long-term durability, while directly addressing prior FDA considerations related to open surgical venous valve replacement. Its transcatheter approach is also expected to broaden adoption by appealing to a wider range of implanting physicians.

enVVe has received FDA IDE approval for its TAVVE pivotal clinical trial. The TAVVE study is a prospective, randomized, multi-center trial safety and measuring both hemodynamic improvement and clinical benefit in up to 220 patients across 40 clinical sites.

Learn About the TAVVE Trial

The enVVe® System

  • Non-surgical, minimally invasive procedure requiring no general anesthesia and no overnight hospital stay
  • Self-expanding frame made from nitinol
  • Frame geometry that accommodates the natural dilation and contraction of the vein and provides a proper fit across a broad range of vein sizes
  • Unique single leaflet design that is laser cut from porcine pericardium tissue to exacting specifications
  • Low profile 13 Fr (4.3 mm) delivery system when crimped, giving it the smallest profile of any replacement valve currently in use for the cardiovascular system

The enVVe System has Significant Evolutionary Improvements Built from Our Clinically Proven First-Generation Surgically Implanted VenoValve

Similarities

  • Glutaraldehyde Cross-Linked Porcine Tissue
  • Mono-Cusp Design
  • Femoral Vein Implant
  • Similar Hemodynamic Conditions
  • Designed to Limit Flow Disturbances
  • Anti-Thrombogenic Properties
  • Hand Sewn
  • Sterilized with Gamma Radiation
  • Deep System Hemodynamic Improvement

Functional Improvements

Leakage

78% Less

Valve Closing Time

45% Faster

Frame Durability

15x Better

Greater Tissue Tensile Strength

272% Stronger

Stronger Suture Retention

143% Stronger

Viral Resistant

4x More

Replacement Venous Valve Technology Validated by Substantial and Sustained Clinical Improvement from the SAVVE VenoValve Pivotal Trial

rVCSS Improvement

%

Patients with a clinical improvement in rVCSS (N=65) at one year

rVCSS Improvement

Average point improvement in patients who showed any improvement

Pain (VAS Scores)

%

Median percent improvement

Ulcer Healing

%

Median ulcer area reduction

Ulcer Healing from First-Generation VenoValve SAVVE Trial Patients

Patients Treated